Sharemaestro company-news research for Alamar Biosciences, Inc. Common Stock (ALMR), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

Latest ALMR news and sentiment

Alamar Biosciences, Inc. Common Stock

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research RSS feed
30-day score50Neutral is 50
Early balanced news score 16/100 evidence confidence 100% direct company focus 5 current stories across 2 publishers
Latest weekly closeUSD 34.85week of 18 Sep 2026
Main news subjectMarket update75/100 share of current news
News data statusPartial6 duplicate stories removed

Current company news

Early balanced news score

5 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone44/100 Published 30-day score50/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Alamar Biosciences, Inc. Common Stock (NASDAQ: ALMR) Stock Price, News & Analysis Kalkine · 05 Sep 2026 22:28

What supports the score

Direct evidence

5 current stories are mapped specifically to ALMR.

What limits the score

Source breadth

Only 2 publishers currently contribute to the measured read.

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.013.

Confidence

Confidence is 16/100, below the threshold for a firm score.

50/100
News scoreEarly balanced news score
16/100
Confidencethin evidence
100%/100
Company news5 company stories
97/100
Story agreement3/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence
01 Sep: 2 stories03 Sep: 1 stories04 Sep: 1 stories05 Sep: 1 stories 01 Sep: tone 43, 2 stories03 Sep: tone 50, 1 stories04 Sep: tone 58, 1 stories05 Sep: tone 50, 1 stories 95505
22 Aug06 Sep20 Sep
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence0
0.013 after freshness weighting
Source breadth40
2 independent publishers
Company relevance100
share tied directly to this company
Freshness4
recency-weighted evidence
Agreement97
how closely stories agree
Publisher mix10
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

23 completed price weeks13 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
17 Apr 2026: close 22.0, indexed 100.024 Apr 2026: close 24.84, indexed 112.901 May 2026: close 25.81, indexed 117.308 May 2026: close 23.96, indexed 108.915 May 2026: close 21.54, indexed 97.922 May 2026: close 20.06, indexed 91.229 May 2026: close 20.44, indexed 92.905 Jun 2026: close 20.54, indexed 93.412 Jun 2026: close 22.0, indexed 100.019 Jun 2026: close 21.96, indexed 99.826 Jun 2026: close 26.67, indexed 121.203 Jul 2026: close 25.94, indexed 117.910 Jul 2026: close 28.42, indexed 129.217 Jul 2026: close 25.95, indexed 118.024 Jul 2026: close 25.88, indexed 117.631 Jul 2026: close 25.36, indexed 115.307 Aug 2026: close 28.46, indexed 129.414 Aug 2026: close 33.16, indexed 150.721 Aug 2026: close 34.24, indexed 155.628 Aug 2026: close 30.71, indexed 139.604 Sep 2026: close 30.8, indexed 140.011 Sep 2026: close 27.89, indexed 126.818 Sep 2026: close 34.85, indexed 158.4 26 Jun 2026: news score 52, close 26.67, 3 stories5203 Jul 2026: news score 50, close 25.94, 7 stories10 Jul 2026: news score 50, close 28.42, 10 stories5017 Jul 2026: news score 50, close 25.95, 13 stories24 Jul 2026: news score 50, close 25.88, 14 stories5031 Jul 2026: news score 51, close 25.36, 14 stories07 Aug 2026: news score 50, close 28.46, 11 stories5014 Aug 2026: news score 64, close 33.16, 37 stories21 Aug 2026: news score 58, close 34.24, 36 stories5828 Aug 2026: news score 54, close 30.71, 32 stories04 Sep 2026: news score 52, close 30.8, 34 stories5211 Sep 2026: news score 50, close 27.89, 11 stories18 Sep 2026: news score 50, close 34.85, 5 stories50 Price index 166.5 124.8 83.1 News score 100 50 0
17 Apr03 Jul18 Sep
Weekly close, indexedSentiment score
26-week price+58.4%latest close 34.85
News score change-2first to latest comparable week
One-week response-9.4%Price reacting lower
Fair-value position+8.3%Near fair-value range
WeekNews scoreCloseWeekly move
18 Sep 202650USD 34.85+25.0%
11 Sep 202650USD 27.89-9.4%
04 Sep 202652USD 30.8+0.3%
28 Aug 202654USD 30.71-10.3%
21 Aug 202658USD 34.24+3.3%
14 Aug 202664USD 33.16+16.5%
07 Aug 202650USD 28.46+12.2%
31 Jul 202651USD 25.36-2.0%
Provisional evidence

News subjects

What is shaping the score

Market update
Market update534 stories · 80%
Earnings431 stories · 20%

Source mix

Where the evidence comes from

10/100 independence
Kalkine Media581 stories · 20%
TipRanks431 stories · 20%
Kalkine501 stories · 20%
Stock Titan501 stories · 20%
GlobeNewswire501 stories · 20%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences4Financial Markets2Finance2Economy Monetary1Earnings1

Earlier readings

How the score has changed

32 comparable readings · 90 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move+050 to 50 · Broadly stable
Observed range49–6750 is the neutral baseline
Evidence depth5stories at latest stored reading · +4
Confidence15/100Provisional · +15
21 Jun50 neutral20 Sep 02:38
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
20 Sep 02:3850-115/100 (-8)5 (-30)Provisional
05 Sep 23:5951-123/100 (-2)35 (+1)Provisional
04 Sep 23:5952+125/100 (+2)34 (+1)Provisional
03 Sep 23:5951-123/100 (-2)33 (+1)Provisional
01 Sep 23:5952-925/100 (-9)32 (-5)Provisional
18 Aug 23:5961-134/100 (-5)37 (+1)Measured
16 Aug 23:5962-239/100 (-7)36 (-1)Measured
14 Aug 23:5964-146/100 (-4)37 (+1)Measured

Source headlines

The news behind the score

Showing 1-5 of 5

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

#1—Not directional
KalkineDirect company coverageStored article

Alamar Biosciences, Inc. Common Stock (NASDAQ: ALMR) Stock Price, News & Analysis

This article provides an overview and analysis of Alamar Biosciences, Inc. (NASDAQ: ALMR) common stock. It includes current stock price data, key metrics, an AI-generated summary highlighting the company's focus on diagnostic assays and associated risks, and peer comparisons. The content emphasizes that the information is for general purposes and does not constitute financial advice.

Financial MarketsLife Sciences
Published
05 Sep 2026 22:28
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 13.0d old
Duplicates
1 consolidated
#258Tone
Kalkine MediaDirect company coverageStored article

Ragusa Robert P. Acquires 5,686 Shares and 25,599 Derivative Securities of Alamar Biosciences

Ragusa Robert P., an insider at Alamar Biosciences, Inc. (NASDAQ:ALMR), was awarded 5,686 shares and 25,599 derivative securities on September 1, 2026. This transaction increased his total holdings to these exact amounts, providing clear insight into his post-transaction ownership. All awards were officially recorded under SEC transaction code A.

FinanceLife Sciences
Published
04 Sep 2026 13:26
News subject
Market update
Why this score
Institutional or insider buying
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Low · 31/100
30-day weight
5.3% of the score · 14.4d old
Duplicates
1 consolidated
#3—Not directional
Stock TitanDirect company coverageScored from headline

Alamar Biosciences (ALMR) director has no reported share holdings

Published
03 Sep 2026 20:33
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 15.1d old
Duplicates
1 consolidated
#4—Not directional
GlobeNewswireDirect company coverageStored article

Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference

Alamar Biosciences, Inc. (Nasdaq: ALMR) announced its participation in the Morgan Stanley 24th Annual Global Healthcare Conference in New York. Management will host a fireside chat on September 15, 2026, at 4:05 p.m. ET, with a webcast available on the company's investor relations website. Alamar Biosciences is a commercial-stage proteomics company focused on early disease detection using its NULISA™ technology and ARGO™ HT System for ultra-high sensitivity protein biomarker detection.

FinanceLife Sciences
Published
01 Sep 2026 20:05
News subject
Market update
Why this score
The headline reports news without a clear direction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 17.1d old
Duplicates
2 consolidated
#543Tone
TipRanksDirect company coverageStored article

Alamar Biosciences Slides As Fed Euphoria Fades

Alamar Biosciences (ALMR) shares are experiencing a pullback as traders take profits following a rapid surge driven by hopes for easier Federal Reserve policy. Despite this short-term volatility, the company's strong Q2 earnings, expanding proteomics partnership in Alzheimer's research, and NULISA technology continue to support its long-term growth story. The current stock movement is attributed more to shifts in market sentiment than changes in analyst forecasts.

EarningsEconomy MonetaryFinancial MarketsLife Sciences
Published
01 Sep 2026 00:14
News subject
Earnings
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 36/100
30-day weight
94.7% of the score · 17.9d old
Duplicates
1 consolidated

Earlier company news

ALMR news archive

76 older headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Older news is kept in the archive

There are 76 older ALMR headlines. Open one page at a time when you need them.

Open older archive

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context